Evolving the science of treating hemophilia.

Throughout its history, Genentech has worked to support Treatment for All by expanding treatment options and supporting hemophilia care.

Over the decades 

We’ve worked hard to support Treatment for All by expanding opportunities for connection and hemophilia care by partnering with those at the forefront of change.

1984

Genentech created the foundation for a new treatment for people with hemophilia

1984: Genentech created the foundation for a new treatment for people with hemophilia

Genentech created the first cloned, virus-free, nonblood-derived factor VIII protein using recombinant DNA (RDNA) technology* 

*Genentech outlicensed worldwide production and marketing of factor VIII.

2002

Working together for the hemophilia community

2002: Working together for the hemophilia community

Genentech begins its partnership with Chugai Pharmaceutical

2012

New research begins

2012: New research begins

Working with Chugai, research begins on innovative approaches to treatment of hemophilia A

2017

Genentech brings a new treatment to market

2017: Genentech brings a new treatment to market

2018

Genentech forms a new global partnership to provide better access to treatment

2018: Genentech forms a new global partnership to provide better access to treatment

Genentech’s parent company, Roche, joins the European Haemophilia Consortium PARTNERS program to provide better treatment access to people with hemophilia A around the world 

2019

We're continuing to deliver on the needs of the community

2019: We're continuing to deliver on the needs of the community

Partnering with WFH

Genentech and our parent company Roche joins the World Federation of Hemophilia Humanitarian Aid Program to provide treatment to people with hemophilia A in developing countries

Your Time to Thrive Workshops

Genentech partners with the University of Pennsylvania Positive Psychology Center to explore how the science of positive psychology can help people with hemophilia thrive in times of change through interactive workshops

CHALLENGE ACCEPTED

Genentech launches its new series, CHALLENGE ACCEPTED, which dives into the real, everyday challenges of living with hemophilia

Save One Life

Genentech and our parent company Roche supports Save One Life’s Micro-Enterprise Grant program to help people with bleeding disorders in developing countries establish or grow their small businesses 

Hemophilia Community Clinical Education Manager thumbnail

Connect With Us

Our Hemophilia Clinical Education Managers (CEMs) serve all 50 states and US territories. They have years of experience as registered nurses with a host of helpful resources—and they can provide opportunities to connect with Genentech and the community at chapter events, conferences, and educational programs.

Clinical Education Managers do not provide medical advice.

Please enter your ZIP Code below.

Meet your nearest Clinical Education Manager:

Please call 1-866-HEMLIBRA (1-866-436-5427) for assistance in contacting a Clinical Education Manager

The ZIP Code you’ve entered is incorrect, please try again.